Compare Brookfield Infrastructure Partners LP (BIP) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs Regeneron Pharmaceuticals Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $38.19 (market cap $17.25B), while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $69.52B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4× Brookfield Infrastructure Partners LP's market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.84%). Which is the better fit depends on your goals.
| BIP | REGN | |
|---|---|---|
Market Cap | $17.25B | $69.52B |
Sector | Industrials | Health |
52-Week High | $40.08 | $812.27 |
52-Week Low | $29.81 | $542.52 |
Enterprise Value | $78.92B | $63.47B |
Dividend Yield | 4.84% | 0.57% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
